

RESPIRATORY DISEASES

PAPER-III

RPD/J/18/42/III

Time: 3 hours

Max. Marks:100

**Important Instructions:**

- Attempt all questions in order.
- Each question carries 10 marks.
- Read the question carefully and answer to the point neatly and legibly.
- Do not leave any blank pages between two answers.
- Indicate the question number correctly for the answer in the margin space
- Answer all the parts of a single question together.
- Start the answer to a question on a fresh page or leave adequate space between two answers.
- Draw table/diagrams/flowcharts wherever appropriate.

Write short notes on:

- |     |   |     |
|-----|---|-----|
| 1.  | a) Primary complex<br>b) Latent tuberculosis  | 5+5 |
| 2.  | a) Role of corticosteroids in management of tuberculosis.<br>b) INH mono-resistance: Implications in tuberculosis control.                                      | 5+5 |
| 3.  | a) Merits and de-merits of shorter regimens for MDR-TB.<br>b) Diagnosis and management of hepatitis due to first line anti-tuberculosis drugs.                  | 5+5 |
| 4.  | a) Strategy of prevention of transmission of tuberculosis in health care workers.<br>b) Causes of secondary drug resistance in TB patients.                     | 5+5 |
| 5.  | a) Complex Sleep apnoea<br>b) Causes of Central Sleep apnoea.   | 5+5 |
| 6.  | a) Role of corticosteroids in patients with septic shock.<br>b) Management of acute exacerbation of COPD in critically ill.                                     | 5+5 |
| 7.  | a) Lung protective ventilation.<br>b) Diagnosis of ventilator associated pneumonia.   | 5+5 |
| 8.  | a) Fluid therapy in patients with septic shock.<br>b) Initial antibiotic therapy in patients with septic shock.   | 5+5 |
| 9.  | a) Causes of difficulty in weaning a patient from mechanical ventilation.<br>b) Role of non-invasive ventilation for management of chronic respiratory failure. | 5+5 |
| 10. | a) Newer drugs for management of MDR-TB.<br>b) Challenges of END TB Strategy.   | 5+5 |

\*\*\*\*\*